• Raised $12.65 million backed by FirstRand, Standard Bank, Allan Gray and SA SME Fund
  • Focused on early-stage startups, including first investment in fintech Tyme Group in commercial banking
  • Supported by major financial institutions, strengthening the credibility of the fund

Endeavor South Africa has closed its Harvest Fund III on $12.65 million to support early-stage startups. The fund, launched in 2023, reached its final close in April 2026, almost three years later, exceeding South African venture capital expectations. It received backing from major financial institutions including FirstRand, Standard Bank, Allan Gray and the SA SME Fund. According to PitchBook, the fund has already invested in Tyme Group, a fintech company generating revenue in commercial banking and serving more than 2 million customers across Africa.

Harvest Fund III is structured as an early-stage venture capital vehicle that provides funding, mentorship and operational support to high-growth startups. The limited partners made their commitments through April 2026, ensuring a diverse and stable capital base designed to minimize risk for both the fund and its portfolio companies. The investment strategy focuses on scalable and innovative businesses, as demonstrated by Tyme Group's support.

Endeavor South Africa said the fund represented “a strong vote of confidence in the future of South African entrepreneurship”. This comes as Africa's early-stage venture capital market expands, with total VC funding expected to reach $305 million in 2025, up 18% year-on-year. Backed by major financial institutions, the fund benefits from strong credibility. According to PitchBook's analysis of South African VC trends, funds backed by top-tier limited partners have historically increased startup follow-on funding by 40-50%.

By targeting early-stage companies like Tyme Group, the fund aims to grow businesses that drive job creation and financial inclusion. Beyond capital, it provides credibility, advice and strategic support, helping startups secure follow-on funding and expansion.

By Cynthia Abbott Takang

Categorized in: